Journal
HEART FAILURE REVIEWS
Volume 27, Issue 5, Pages 1559-1565Publisher
SPRINGER
DOI: 10.1007/s10741-021-10163-0
Keywords
Transthyretin; Light chain; Multiple myeloma; Immunoglobulin; Heart failure; Cardiomyopathy
Categories
Ask authors/readers for more resources
Amyloidosis is a multisystem disease that requires coordinated care and treatment involving multiple specialists. Establishing comprehensive amyloidosis programs within healthcare institutions can help improve patient care through multidisciplinary collaboration, clear program goals, institutional support, and focus on program growth and development. The creation and growth of such programs have the potential to increase awareness of the disease and benefit both patients and institutions.
Amyloidosis is a multisystem disease which continues to present in later stages due to delayed diagnosis. Once the disease is identified, the coordination of ongoing care and treatment becomes complex and often involves multiple specialists. As knowledge of the disease grows, healthcare providers within institutions have organized to create comprehensive amyloidosis programs to better serve patients in the region. In this review, we present considerations in starting a cardiac amyloidosis program from two institutions that have recently started such programs. Identification of multidisciplinary stakeholders, development of overarching program goals, creation of institutional buy-in, and emphasis on program growth and development are tenets of a successful program. The creation and growth of an amyloidosis program has the potential to raise awareness for the disease and benefit patients and institutions alike.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available